Nitib 140mg Capsules

Product Description

Nitib 140 mg Capsules contain Nilotinib, which is a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia, specifically Chronic Myeloid Leukemia (CML). CML is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the bloodstream. Nilotinib is used to target and inhibit the BCR-ABL fusion protein, which plays a key role in the development of CML.

Key Uses:

1. Chronic Myeloid Leukemia (CML): Nitib 140 mg is used in the treatment of CML in patients who are Philadelphia chromosome-positive (Ph+ CML), both in chronic phase and in accelerated phase. It is also used for patients who have resistant or intolerant responses to other treatments, such as Imatinib.

2. Targeted Cancer Therapy: It is a part of targeted cancer therapy, specifically for cancers driven by the BCR-ABL protein, which Nilotinib specifically inhibits.

Mechanism of Action:

Nilotinib works by inhibiting the BCR-ABL tyrosine kinase. The BCR-ABL fusion protein, which results from a genetic mutation in CML, signals cancer cells to grow uncontrollably. By blocking this signaling pathway, Nilotinib prevents the proliferation of leukemia cells and helps to control the disease.

Common Side Effects:

• Headache.
• Nausea or vomiting.
• Fatigue or weakness.
• Rash.
• Elevated liver enzymes: Liver function tests may show increased levels, indicating potential liver issues.
• Muscle or joint pain.

Serious Side Effects:

• Cardiovascular effects: Nilotinib can cause serious heart-related side effects such as QT interval prolongation (which can lead to arrhythmias) or heart failure. Regular heart monitoring may be needed.
• Liver toxicity: There is a risk of severe liver problems. Regular monitoring of liver function is recommended.
• Pancreatitis: Nilotinib can sometimes lead to inflammation of the pancreas, causing severe abdominal pain and other symptoms.
• Low blood counts: Nilotinib can decrease white blood cells, red blood cells, and platelets, leading to infections, anemia, or bleeding.

Dosage:

The usual recommended dose of Nitib (Nilotinib) is 300 mg twice daily, though the dosage can be adjusted based on the patient's condition and response to treatment. Nitib 140 mg capsules may be used as part of a dose escalation or maintenance regimen.

Precautions:

• Cardiac monitoring: Patients on Nilotinib should undergo ECG monitoring for QT interval prolongation before and during treatment.
• Liver function: Liver enzymes should be checked regularly as Nilotinib can cause liver toxicity.
• Drug interactions: Nilotinib can interact with other drugs, so it is important to inform the healthcare provider about all medications the patient is taking, including over-the-counter drugs.
• Pregnancy and breastfeeding: Nilotinib should be avoided during pregnancy due to potential harm to the fetus, and it is not recommended during breastfeeding.

Summary:

Nitib 140 mg Capsules (Nilotinib) is a targeted therapy used in the treatment of Chronic Myeloid Leukemia (CML), particularly for patients who have resistance or intolerance to other therapies like Imatinib. It works by inhibiting the BCR-ABL protein, which causes cancer cell proliferation. Common side effects include nausea, fatigue, and rashes, while serious side effects may include heart problems, liver toxicity, and low blood counts. Regular monitoring of liver function and heart health is essential during treatment.